These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12065709)

  • 1. Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor.
    Billah MM; Cooper N; Minnicozzi M; Warneck J; Wang P; Hey JA; Kreutner W; Rizzo CA; Smith SR; Young S; Chapman RW; Dyke H; Shih NY; Piwinski JJ; Cuss FM; Montana J; Ganguly AK; Egan RW
    J Pharmacol Exp Ther; 2002 Jul; 302(1):127-37. PubMed ID: 12065709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
    Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
    J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig.
    Underwood DC; Bochnowicz S; Osborn RR; Kotzer CJ; Luttmann MA; Hay DW; Gorycki PD; Christensen SB; Torphy TJ
    J Pharmacol Exp Ther; 1998 Dec; 287(3):988-95. PubMed ID: 9864284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and profile of SCH351591, a novel PDE4 inhibitor.
    Billah M; Cooper N; Cuss F; Davenport RJ; Dyke HJ; Egan R; Ganguly A; Gowers L; Hannah DR; Haughan AF; Kendall HJ; Lowe C; Minnicozzi M; Montana JG; Naylor R; Oxford J; Peake JC; Piwinski JJ; Runcie KA; Sabin V; Sharpe A; Shih NY; Warneck JB
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1621-3. PubMed ID: 12039576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.
    Giembycz MA
    Expert Opin Investig Drugs; 2001 Jul; 10(7):1361-79. PubMed ID: 11772257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
    Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
    Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor.
    Raeburn D; Underwood SL; Lewis SA; Woodman VR; Battram CH; Tomkinson A; Sharma S; Jordan R; Souness JE; Webber SE
    Br J Pharmacol; 1994 Dec; 113(4):1423-31. PubMed ID: 7889300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294.
    Gale DD; Hofer P; Spina D; Seeds EA; Banner KH; Harrison S; Douglas G; Matsumoto T; Page CP; Wong RH; Jordan S; Smith F; Banik N; Halushka PV; Cavalla D; Rotshteyn Y; Kyle DJ; Burch RM; Chasin M
    Pulm Pharmacol Ther; 2003; 16(2):97-104. PubMed ID: 12670778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
    Huang Z; Dias R; Jones T; Liu S; Styhler A; Claveau D; Otu F; Ng K; Laliberte F; Zhang L; Goetghebeur P; Abraham WM; Macdonald D; Dubé D; Gallant M; Lacombe P; Girard Y; Young RN; Turner MJ; Nicholson DW; Mancini JA
    Biochem Pharmacol; 2007 Jun; 73(12):1971-81. PubMed ID: 17428447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
    Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
    Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration.
    Kuss H; Hoefgen N; Johanssen S; Kronbach T; Rundfeldt C
    J Pharmacol Exp Ther; 2003 Oct; 307(1):373-85. PubMed ID: 12944497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDP840. A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors.
    Alexander RP; Warrellow GJ; Eaton MA; Boyd EC; Head JC; Porter JR; Brown JA; Reuberson JT; Hutchinson B; Turner P; Boyce B; Barnes D; Mason B; Cannell A; Taylor RJ; Zomaya A; Millican A; Leonard J; Morphy R; Wales M; Perry M; Allen RA; Gozzard N; Hughes B; Higgs G
    Bioorg Med Chem Lett; 2002 Jun; 12(11):1451-6. PubMed ID: 12031318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
    Burnouf C; Auclair E; Avenel N; Bertin B; Bigot C; Calvet A; Chan K; Durand C; Fasquelle V; Féru F; Gilbertsen R; Jacobelli H; Kebsi A; Lallier E; Maignel J; Martin B; Milano S; Ouagued M; Pascal Y; Pruniaux MP; Puaud J; Rocher MN; Terrasse C; Wrigglesworth R; Doherty AM
    J Med Chem; 2000 Dec; 43(25):4850-67. PubMed ID: 11123995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations.
    Draheim R; Egerland U; Rundfeldt C
    J Pharmacol Exp Ther; 2004 Feb; 308(2):555-63. PubMed ID: 14610230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.
    Hughes B; Howat D; Lisle H; Holbrook M; James T; Gozzard N; Blease K; Hughes P; Kingaby R; Warrellow G; Alexander R; Head J; Boyd E; Eaton M; Perry M; Wales M; Smith B; Owens R; Catterall C; Lumb S; Russell A; Allen R; Merriman M; Bloxham D; Higgs G
    Br J Pharmacol; 1996 Jul; 118(5):1183-91. PubMed ID: 8818342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
    Hatzelmann A; Schudt C
    J Pharmacol Exp Ther; 2001 Apr; 297(1):267-79. PubMed ID: 11259554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
    Buckley GM; Cooper N; Davenport RJ; Dyke HJ; Galleway FP; Gowers L; Haughan AF; Kendall HJ; Lowe C; Montana JG; Oxford J; Peake JC; Picken CL; Richard MD; Sabin V; Sharpe A; Warneck JB
    Bioorg Med Chem Lett; 2002 Feb; 12(3):509-12. PubMed ID: 11814830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs.
    Dent G; Poppe H; Egerland J; Marx D; Szelenyi I; Branscheid D; Magnussen H; Rabe KF
    Pulm Pharmacol Ther; 1998 Feb; 11(1):13-21. PubMed ID: 9802959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs.
    Santing RE; Olymulder CG; Van der Molen K; Meurs H; Zaagsma J
    Eur J Pharmacol; 1995 Feb; 275(1):75-82. PubMed ID: 7774665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.
    Griswold DE; Webb EF; Badger AM; Gorycki PD; Levandoski PA; Barnette MA; Grous M; Christensen S; Torphy TJ
    J Pharmacol Exp Ther; 1998 Nov; 287(2):705-11. PubMed ID: 9808700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.